GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Institutional Ownership

Orthocell (ASX:OCC) Institutional Ownership : 0.66% (As of Apr. 16, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Orthocell Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orthocell's institutional ownership is 0.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orthocell's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orthocell's Float Percentage Of Total Shares Outstanding is 0.00%.


Orthocell Institutional Ownership Historical Data

The historical data trend for Orthocell's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Institutional Ownership Chart

Orthocell Historical Data

The historical data trend for Orthocell can be seen below:

2022-04-30 2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2025-03-31
Institutional Ownership 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.66

Orthocell Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Orthocell Business Description

Traded in Other Exchanges
N/A
Address
90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.